Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 285

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 285
---
 settled in an entity’s own equity. ASU 2020 -06amends the diluted earnings per share guidance, including the requirement to use the if -convertedmethod for all convertible instruments. ASU 2020 -06is effective for fiscal years beginning after December 15, 2023 and should be applied on a full or modified retrospective basis. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted ASU 2020 -06as of inception, May 23, 2024. There was no effect to the Company’s presented financial statements. Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements. F-11 DRUGS MADE IN AMERICA ACQUISITION CORP.
NOTES TO FINANCIAL STATEMENTS
MAY 23, 2024 (INCEPTION) THROUGH SEPTEMBER 30, 2024 NOTE 3 — PROPOSED PUBLIC OFFERING Pursuant to the Proposed Public Offering, the Company intends to offer for sale 20,000,000 Units (or 23,000,000 Units if the underwriters’ over -allotmentoption is exercised in full) at a price of $10.00 per Unit. Each Unit will consist of one ordinary share and one right (“Public Right”), with each Public Right entitling the holder to receive one -eighth(1/8) of one ordinary share upon the consummation of an initial business combination. NOTE 4 — PRIVATE PLACEMENT The Sponsor has agreed to purchase an aggregate of 400,000 Private Placement Units (or 430,000 Private Placement Units if the underwriters’ over -allotmentis exercised in full) at a price of $10.00 per Private Placement Unit ($4,000,000, or an aggregate of $4,300,000 if the underwriters’ over -allotmentis exercised in full) from the Company in a private placement that will occur simultaneously with the closing of the Proposed Public Offering. Each Private Placement Unit will consist of one ordinary share and one right to receive one -eighth(1/8) of one ordinary share upon the consummation of an initial business combination. The proceeds from the sale of the Private Placement Units will be added to the net proceeds from the Proposed Public Offering held in the Trust Account.